当前位置：
X-MOL 学术
›
Neuromodulation
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Initial Intrathecal Dose Titration and Predictors of Early Dose Escalation in Patients With Cancer Using a 100:1 Oral to Intrathecal Morphine Conversion Ratio
Neuromodulation: Technology at the Neural Interface ( IF 2.8 ) Pub Date : 2021-08-10 , DOI: 10.1111/ner.13517 Jill E. Sindt 1 , Daniel W. Odell 1 , Rayhan Tariq 1 , Angela P. Presson 1 , Chong Zhang 1 , Shane E. Brogan 1
Neuromodulation: Technology at the Neural Interface ( IF 2.8 ) Pub Date : 2021-08-10 , DOI: 10.1111/ner.13517 Jill E. Sindt 1 , Daniel W. Odell 1 , Rayhan Tariq 1 , Angela P. Presson 1 , Chong Zhang 1 , Shane E. Brogan 1
Affiliation
Pain is common in patients with advanced cancer, and intrathecal drug delivery (IDD) has been successfully used for recalcitrant pain. We report on our experience using a 100:1 oral-to-intrathecal morphine conversion ratio for initial dosing and factors predictive of early dose escalation.
中文翻译：
使用 100:1 口服与鞘内吗啡转化率的癌症患者的初始鞘内剂量滴定和早期剂量递增的预测因素
疼痛在晚期癌症患者中很常见，鞘内给药 (IDD) 已成功用于治疗顽固性疼痛。我们报告了我们使用 100:1 口服对鞘内吗啡转化率进行初始给药的经验和早期剂量递增的预测因素。
更新日期：2021-08-10
中文翻译：
使用 100:1 口服与鞘内吗啡转化率的癌症患者的初始鞘内剂量滴定和早期剂量递增的预测因素
疼痛在晚期癌症患者中很常见，鞘内给药 (IDD) 已成功用于治疗顽固性疼痛。我们报告了我们使用 100:1 口服对鞘内吗啡转化率进行初始给药的经验和早期剂量递增的预测因素。
京公网安备 11010802027423号